Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's KeytrudaProactive Investors • 05/18/26
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic AreasGlobeNewsWire • 05/18/26
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic AreasBusiness Wire • 05/18/26
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic MelanomaGlobeNewsWire • 05/16/26
UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering FairGlobeNewsWire • 05/15/26
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering FairGlobeNewsWire • 05/15/26
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/12/26
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive YearsGlobeNewsWire • 05/08/26
Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 TrialGlobeNewsWire • 05/05/26
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD StrengthZacks Investment Research • 04/29/26
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to SayZacks Investment Research • 04/29/26
Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter DrugInvestors Business Daily • 04/29/26